Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein $E^{-/-}$ Mice

  • Lee, Bok-Soo (Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Choi, Jin-Yong (Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Joo-Yun (Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Han, Seul-Hee (Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Jeong-Euy (Department of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Published : 2012.08.31
⟨ Previous Next ⟩

Abstract

Background and Objectives: Since statins and angiotensin receptor blockers are a frequently prescribed combination in patients with atherosclerotic cardiovascular diseases, we tested the interactive effects of simvastatin and losartan on atherosclerosis in apolipoprotein E $(apoE)^{-/-}$ mice. Materials and Methods: Apolipoprotein $E^{-/-}$ mice were fed a high-fat, high-cholesterol (HFHC) diet for 12 weeks, with and without simvastatin (40 mg/kg) and/or losartan (20 mg/kg). The mice were divided into 5 groups and were fed as follows: regular chow (control diet, n=5), HFHC diet (n=6), HFHC diet with losartan (n=6), HFHC diet with simvastatin (n=6), and HFHC diet with both losartan and simvastatin (n=6). Results: Losartan treatment in $apoE^{-/-}$ mice significantly decreased atherosclerotic lesion areas in whole aortic strips stained with Oil Red O. The plaque area measured at the aortic sinus level was reduced significantly by 17% (HFHC; $346830.9{\pm}52915.8\;{\mu}m^2$ vs. HFHC plus losartan; $255965.3{\pm}74057.7\;{\mu}m^2$, p<0.05) in the losartan-treated group. Simvastatin and simvastatin plus losartan treatments reduced macrophage infiltration into lesions by 33% (HFHC; $183575.6{\pm}43211.2\;{\mu}m^2$ vs. HFHC plus simvastatin; $120556.0{\pm}39282.8\;{\mu}m^2$, p<0.05) and 44% (HFHC; $183575.6{\pm}43211.2\;{\mu}m^2$ vs. HFHC plus simvastatin and losartan; $103229.0{\pm}8473.3\;{\mu}m^2$, p<0.001, respectively). In mice fed the HFHC diet alone, the smooth muscle cell layer in the aortic media was almost undetectable. In mice co-treated with losartan and simvastatin, the smooth muscle layer was more than 60% preserved (p<0.05). Given alone, losartan showed a slightly stronger effect than simvastatin; however, treatment with losartan plus simvastatin induced a greater inhibitory effect on atherosclerosis than either drug given alone. Serum lipid profiles did not differ significantly among the groups. Conclusion: Losartan displayed anti-atherosclerotic effects in $apoE^{-/-}$ mice that were equivalent to or greater than the effects of simvastatin. Combined treatment with these drugs had greater effect than either drug alone.

Keywords

References

  1. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by highresolution, noninvasive magnetic resonance imaging. Circulation 2001; 104:249-52. https://doi.org/10.1161/01.CIR.104.3.249
  2. Oliver MF, de Feyter PJ, Lubsen J, et al. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8. https://doi.org/10.1016/S0140-6736(94)92082-6
  3. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002;106:2884-7. https://doi.org/10.1161/01.CIR.0000041255.88750.F0
  4. Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001;104:387-92. https://doi.org/10.1161/hc2901.093188
  5. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70. https://doi.org/10.1001/jama.286.1.64
  6. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-9. https://doi.org/10.1172/JCI1500
  7. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007;204:2449-60. https://doi.org/10.1084/jem.20070657
  8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Reserarch Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. https://doi.org/10.1001/jama.288.23.2981
  9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. https://doi.org/10.1056/NEJM200001203420301
  10. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51. https://doi.org/10.1016/S0140-6736(04)16456-8
  11. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3
  12. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8. https://doi.org/10.1161/01.RES.74.6.1141
  13. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110:3687-92. https://doi.org/10.1161/01.CIR.0000143085.86697.13
  14. Han SH, Koh KK, Quon MJ, Lee Y, Shin EK. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 2007;190:205-11. https://doi.org/10.1016/j.atherosclerosis.2006.01.021
  15. Bayorh MA, Layas MF, Mann G, Feuerstein GZ, Eatman D. The effect of diet on simvastatin and losartan enhancement of endothelial function. Clin Exp Hypertens 2007;29:311-25. https://doi.org/10.1080/10641960701500463
  16. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. https://doi.org/10.1016/S0140-6736(03)12948-0
  17. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648-57. https://doi.org/10.1016/S0008-6363(00)00146-2
  18. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? a meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62. https://doi.org/10.1016/j.jacc.2005.05.085
  19. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748
  20. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21. https://doi.org/10.1161/01.ATV.21.1.115
  21. Hayek T, Attias J, Coleman R, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999;44:579-87. https://doi.org/10.1016/S0008-6363(99)00239-4
  22. Kim SH, Lee ES, Lee JY, et al. Multiplex coherent anti-stokes Raman spectroscopy images intact atheromatous lesions and concomitantly identifies distinct chemical profiles of atherosclerotic lipids. Circ Res 2010;106:1332-41. https://doi.org/10.1161/CIRCRESAHA.109.208678
  23. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194-9. https://doi.org/10.1161/01.ATV.0000022694.16328.CC
  24. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C, Karakiulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol 2001;38:715-28. https://doi.org/10.1097/00005344-200111000-00008
  25. Chen H, Li D, Mehta JL. Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2002;39:332-9. https://doi.org/10.1097/00005344-200203000-00003
  26. Park HK, Park EC, Bae SW, et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation 2006;114:886-93. https://doi.org/10.1161/CIRCULATIONAHA.105.541219
  27. Martin-Ventura JL, Duran MC, Blanco-Colio LM, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 2004;110:2216-9. https://doi.org/10.1161/01.CIR.0000136814.87170.B1

Cited by

  1. Arterial hypertension and coronary heart disease: the place of angiotensin II receptor antagonists vol.11, pp.6, 2012, https://doi.org/10.15829/1728-8800-2012-6-78-80
  2. Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations vol.20, pp.8, 2012, https://doi.org/10.1089/ars.2013.5531
  3. Statins and Renin-Angiotensin System Inhibitor Combination Treatment to Prevent Cardiovascular Disease vol.78, pp.2, 2012, https://doi.org/10.1253/circj.cj-13-1494
  4. Impact of losartan and angiotensin II on the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat vascular smooth muscle cells vol.11, pp.3, 2012, https://doi.org/10.3892/mmr.2014.2952
  5. Magnetic Nanoparticles Conjugated with Peptides Derived from Monocyte Chemoattractant Protein-1 as a Tool for Targeting Atherosclerosis vol.10, pp.2, 2012, https://doi.org/10.3390/pharmaceutics10020062
  6. The potential therapeutic use of renin–angiotensin system inhibitors in the treatment of inflammatory diseases vol.234, pp.3, 2012, https://doi.org/10.1002/jcp.27205
  7. Optimal Carotid Plaque Features on Computed Tomography Angiography Associated With Ischemic Stroke vol.10, pp.5, 2012, https://doi.org/10.1161/jaha.120.019462
  8. A Standardized Lindera obtusiloba Extract Improves Endothelial Dysfunction and Attenuates Plaque Development in Hyperlipidemic ApoE-Knockout Mice vol.10, pp.11, 2021, https://doi.org/10.3390/plants10112493